Department of Medicine, St. Luke's Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10019, USA.
Clin Colorectal Cancer. 2010 Jan;9(1):55-8. doi: 10.3816/CCC.2010.n.008.
Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing vascular endothelial growth factor. Adverse events resulting from its use include gastrointestinal perforation, wound-healing complications, hemorrhage, and arterial thromboembolism. We present a case of a 67-year-old man who developed Fournier's gangrene during treatment with bevacizumab 4 months after completing mFOLFOX6 (5-FU/leucovorin/oxaliplatin) for CRC. Other than bevacizumab, the patient had no medications and had no medical conditions that would predispose to Fournier's gangrene.
贝伐珠单抗是一种人源化单克隆抗体，经美国食品药品监督管理局批准与基于氟尿嘧啶（FU）的化疗联合用于转移性结直肠癌（CRC）患者的一线治疗。其作用机制是通过中和血管内皮生长因子来抑制肿瘤血管生成。使用该药导致的不良反应包括胃肠道穿孔、伤口愈合并发症、出血和动脉血栓栓塞。我们报告了 1 例 67 岁男性患者，在接受 mFOLFOX6（5-氟尿嘧啶/亚叶酸/奥沙利铂）治疗 CRC 4 个月后使用贝伐珠单抗时发生了福尼尔坏疽。除了贝伐珠单抗，该患者没有使用其他药物，也没有导致福尼尔坏疽的易患医学状况。
